Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG

PHASE3CompletedINTERVENTIONAL
Enrollment

515

Participants

Timeline

Start Date

September 30, 1998

Primary Completion Date

October 31, 2002

Study Completion Date

October 31, 2002

Conditions
Carcinoma, Small Cell Lung
Interventions
BIOLOGICAL

BEC2 Vaccine

5 vaccinations of BEC2 (2.5 mg) + BCG given day 1 of weeks 0,2,4,6 \& 10.

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

collaborator

EORTC Lung Cancer Cooperative Group

OTHER

collaborator

Spanish Lung Cancer Group

OTHER

collaborator

Schweizerische Arbeitsgruppe fuer angewandte Krebsforschung (SAKK)

UNKNOWN

collaborator

US Department of Veterans Affairs

FED

collaborator

Groupe Francais De Pneumo-Cancerologie

OTHER

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

Independent centers (Australia, New Zealand, Europe, USA)

UNKNOWN

lead

Eli Lilly and Company

INDUSTRY

NCT00037713 - Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG | Biotech Hunter | Biotech Hunter